86MO Personalized molecularly matched therapies for carcinomas of unknown primary is associated with improved outcomes

Autor: Adashek, J.J., Kato, S., Gumas, S., Lee, S., Okamura, R., Sicklick, J., Kurzrock, R.

Publikováno v: In Annals of Oncology September 2020 31 Supplement 4:S275-S276

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary.

Autor: Kato S; Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, La Jolla, CA., Weipert C; Guardant Health, Redwood City, CA., Gumas S; Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, La Jolla, CA., Okamura R; Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, La Jolla, CA.; Department of Surgery, Kyoto University Hospital, Kyoto, Japan., Lee S; Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, La Jolla, CA., Sicklick JK; Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, La Jolla, CA.; Department of Surgery, Division of Surgical Oncology, UC San Diego School of Medicine, San Diego, CA., Saam J; Guardant Health, Redwood City, CA., Kurzrock R; WIN Consortium for Precision Medicine, Villejuif, France.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2021 Nov 03; Vol. 5. Date of Electronic Publication: 2021 Nov 03 (Print Publication: 2021).